Russell Investments Group Ltd. reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,532 shares of the company’s stock after selling 7,060 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.10% of Axsome Therapeutics worth $9,871,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ABS Investment Management LLC acquired a new position in Axsome Therapeutics in the 2nd quarter valued at approximately $171,339,000. ABS Direct Equity Fund LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter worth approximately $60,000. Jacobi Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter valued at $47,000. Silvant Capital Management LLC acquired a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at $66,000. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Axsome Therapeutics by 505.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 339 shares of the company’s stock valued at $83,000 after buying an additional 283 shares during the period. 81.49% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, COO Mark Jacobson sold 10,000 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares of the company’s stock, valued at $2,086,500. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.60% of the stock is currently owned by company insiders.
Axsome Therapeutics Stock Performance
Shares of NASDAQ AXSM opened at $129.36 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.34 and a current ratio of 1.42. The firm has a market cap of $6.80 billion, a price-to-earnings ratio of -42.27 and a beta of 0.86. The business’s 50-day simple moving average is $163.75 and its 200-day simple moving average is $195.47. Axsome Therapeutics, Inc. has a 52 week low of $123.00 and a 52 week high of $260.19.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.38. The firm had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The company’s revenue for the quarter was up 51.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.94) EPS. As a group, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on AXSM shares. Zacks Research upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Needham & Company LLC increased their price objective on Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Deutsche Bank cut their price objective on Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Truist Financial lifted their price objective on Axsome Therapeutics from $200.00 to $285.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Finally, Royal Bank Of Canada reduced their price objective on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $266.21.
Get Our Latest Stock Analysis on AXSM
Axsome Therapeutics Company Profile
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Further Reading
- Five stocks we like better than Axsome Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
